Navigation Links
KellBenx Secures Exclusive Worldwide License With AdnaGen for Commercializing Patented Antibodies
Date:4/6/2011

NEW YORK, April 6, 2011 /PRNewswire/ -- KellBenx, a biotechnology company focused on the development of non-invasive prenatal diagnosis (NIPD) of genetic and inherited disorders, announced today that it has signed an exclusive agreement with AdnaGen, a wholly-owned subsidiary of Alere, Inc., to license specific antibodies. Under the agreement, KellBenx will have exclusive worldwide rights to commercialize the antibodies, which enable the extraction of clinically relevant information from maternal blood through a test that could be widely available as early as 2012.

Fetal Nucleated Red Blood Cells (FNRBCs), which have been identified in maternal blood, can be a source for monitoring and diagnosis of maternal, fetal, and neo-natal health and disease. The KellBenx process involves the enrichment of these FNRBCs with the antibodies licensed from AdnaGen to perform chromosomal or genetic analysis to identify markers of potential disorders. With these antibodies, known as Monoclonal Antibodies with Specificity for Fetal Erythroid Cells, KellBenx will be able to launch clinical trials of its non-invasive test.

"We are delighted to secure a license that allows KellBenx to use the AdnaGen antibodies," said Hassan Bennani, MD., CEO of KellBenx. "This agreement creates the opportunity to begin clinical testing of the exciting laboratory results we have produced over the past year, and it brings us one step closer to bringing a non-invasive prenatal blood test to the market that can detect genetic disorders."

"We're pleased to be able to help KellBenx advance a technology that could have a profound impact on the detection and diagnosis of fetal and neonatal genetic disorders," said Alexander L. Weis, Managing Director of AdnaGen AG. "Our proprietary antibodies will enable the clinical tests that could make this non-invasive testing a reality."

About KellBenx

Founded in 2010, KellBenx, Inc. is a privately-held biotechnology company based in New York City. KellBenx is developing high value, innovative tests that leverage the ability to extract clinically relevant information from blood.  Our focus is to improve women's healthcare and one of our first tests is in the area of non-invasive prenatal diagnosis (NIPD) for genetic disorders. For more information, please call 631-643-2614 or visit kellbenx.com.


'/>"/>
SOURCE KellBenx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film
2. Core Essence Secures $11.5 Million Series B Financing
3. CardioFocus Secures $5M Credit Facility with Silicon Valley Bank
4. Vystar® Corporation Secures a $3M Credit Facility to Fund Growth
5. Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation
6. PLC Systems Secures $4 Million in Financing
7. Biomatrica Secures Strategic Investment from IQT
8. Digital Assent Secures $2 Million Series A Financing to Grow PatientPad Point-of-Care Network
9. TechniScan Secures $10 Million Equity Financing Facility
10. Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility
11. MedShape Solutions, Inc. Secures Investment From IQT to Support U.S. Intelligence Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... 27, 2016 Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that ... at two upcoming investor conferences: SeeThru Equity MicroCap ... New York City , NY When: ... Marcum MicroCap Conference   Where: Grand Hyatt Hotel, 109 ...
(Date:5/26/2016)... May 26, 2016   Change Healthcare ... analytics, network solutions and technology-enabled services designed ... entered into a strategic channel partnership with ... software solutions and revenue cycle management services ... and rehabilitation clinics to optimize revenue, operational ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, 2016 ... ; Frankfurt Prime Standard: QIA) today announced that the company ... Diagnostics GmbH to develop and commercialize predictive assays in oncology. ... as a marker to predict effectiveness of anthracycline treatment in ... "We are pleased to partner with Therawis, which developed the ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of acute stroke ... a sustainable product to aid in the rehabilitation process has steadily increased. Ekso Bionics ... individuals with hemiplegia due to stroke. , Ekso Bionics has now received clearance from ...
(Date:5/27/2016)... , ... May 27, 2016 , ... Beleza Medspa ... body fat composition regulations. This is the first time that Coolsculpting is being ... at least every six months to ensure they meet the prescribed body-fat standard, measured ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team ... and food industries. Aside from its GMP accreditation, Validation Center is also a ... certified products, services and staff. , Validation Center is ISO17025 accredited and only ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... of thousands of defective respirators, according to court documents and SEC filings. ... William and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles ...
(Date:5/26/2016)... Washington, D.C. (PRWEB) , ... May 26, 2016 , ... ... the men and women who lost their lives in military battle for the country. ... discount cards in 2015 to provide more programs that empower independence for disabled military ...
Breaking Medicine News(10 mins):